普拉西斯精密藥品公司(納斯達克代碼：PRAX)空頭股數銷量大幅下降

Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Rating) was the recipient of a significant decrease in short interest during the month of June. As of June 15th, there was short interest totalling 2,880,000 shares, a decrease of 29.8% from the May 31st total of 4,100,000 shares. Approximately 7.8% of the shares of the stock are sold short. Based on an average trading volume of 1,510,000 shares, the days-to-cover ratio is presently 1.9 days.

In other Praxis Precision Medicines news, Director Dean J. Mitchell purchased 25,000 shares of the business's stock in a transaction dated Wednesday, June 8th. The shares were bought at an average price of $1.81 per share, for a total transaction of $45,250.00. Following the completion of the acquisition, the director now owns 25,000 shares in the company, valued at $45,250. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marcio Souza purchased 27,000 shares of the business's stock in a transaction dated Wednesday, June 8th. The shares were acquired at an average price of $1.85 per share, for a total transaction of $49,950.00. Following the acquisition, the chief executive officer now owns 189,184 shares of the company's stock, valued at approximately $349,990.40. The disclosure for this purchase can be found here. Insiders bought 72,500 shares of company stock valued at $130,815 in the last three months. Company insiders own 10.50% of the company's stock.

Get

Praxis Precision Medicines

alerts:

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Eventide Asset Management LLC raised its holdings in shares of Praxis Precision Medicines by 15.3% during the first quarter. Eventide Asset Management LLC now owns 4,395,000 shares of the company's stock valued at $44,873,000 after purchasing an additional 584,401 shares during the period. Vanguard Group Inc. increased its position in shares of Praxis Precision Medicines by 0.9% during the first quarter. Vanguard Group Inc. now owns 3,322,140 shares of the company's stock worth $33,918,000 after acquiring an additional 29,697 shares in the last quarter. BlackRock Inc. lifted its position in Praxis Precision Medicines by 1.3% in the 1st quarter. BlackRock Inc. now owns 2,529,761 shares of the company's stock valued at $25,828,000 after acquiring an additional 33,065 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Praxis Precision Medicines by 13.9% during the 4th quarter. Alliancebernstein L.P. now owns 1,873,510 shares of the company's stock valued at $36,908,000 after purchasing an additional 228,502 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in Praxis Precision Medicines by 27.2% during the 4th quarter. Point72 Asset Management L.P. now owns 1,446,393 shares of the company's stock worth $28,494,000 after purchasing an additional 309,398 shares in the last quarter. Hedge funds and other institutional investors own 96.25% of the company's stock.

A number of equities analysts have recently commented on the stock. HC Wainwright cut their price target on shares of Praxis Precision Medicines from $48.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, June 7th. Wedbush lowered shares of Praxis Precision Medicines from an "outperform" rating to a "neutral" rating and set a $4.00 price target on the stock. in a report on Monday, June 6th. Piper Sandler cut their price target on shares of Praxis Precision Medicines from $65.00 to $18.00 and set an "overweight" rating on the stock in a report on Tuesday, June 7th. Finally, Bank of America lowered shares of Praxis Precision Medicines from a "buy" rating to a "neutral" rating and set a $4.00 target price on the stock. in a report on Tuesday, June 7th.

Shares of NASDAQ PRAX opened at $2.51 on Tuesday. The firm's 50-day moving average price is $6.07 and its 200-day moving average price is $10.93. Praxis Precision Medicines has a 1-year low of $1.63 and a 1-year high of $23.56.

Praxis Precision Medicines (NASDAQ:PRAX – Get Rating) last announced its quarterly earnings data on Monday, May 9th. The company reported ($1.51) earnings per share for the quarter, missing the consensus estimate of ($1.29) by ($0.22). During the same quarter in the previous year, the business posted ($0.71) EPS. Equities analysts anticipate that Praxis Precision Medicines will post -4.27 EPS for the current year.

Praxis Precision Medicines Company Profile (Get Rating)

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor.

Further Reading

• Get a free copy of the StockNews.com research report on Praxis Precision Medicines (PRAX)
• Basset Furniture Quietly Proves Its Value
• Earnings Revisions: Why You Shouldn't Count On A Rebound In Stocks ... Yet
• Hello Group Stock is Attractive Value Speculators
• PVH Corp Stock Approaching Key Support Levels
• PetVivo Holdings Is A Growth Stock Worth a Look

Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.